Cargando…

PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy

Lung cancer remains the leading cause of cancer-related death worldwide, with one-third diagnosed with locally advanced (stage III) disease. Preoperative induction chemo-radiotherapy is key for the treatment of these patients, however conventional cisplatin based approaches has apparently reached a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cruz-Bermúdez, Alberto, Vicente-Blanco, Ramiro J., Laza-Briviesca, Raquel, García-Grande, Aránzazu, Laine-Menéndez, Sara, Gutiérrez, Lourdes, Calvo, Virginia, Romero, Atocha, Martín-Acosta, Paloma, García, José Miguel, Provencio, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709355/ https://www.ncbi.nlm.nih.gov/pubmed/29192176 http://dx.doi.org/10.1038/s41598-017-17009-6

Ejemplares similares

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2021)

Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
por: Romero, Atocha, et al.
Publicado: (2020)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021)

CB(2) cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway
por: Martínez-Martínez, Esther, et al.
Publicado: (2016)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
por: Serna-Blasco, R., et al.
Publicado: (2021)

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
por: Provencio, Mariano, et al.
Publicado: (2017)

Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma
por: Blanco, Mariola, et al.
Publicado: (2022)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma
por: Bellas, Carmen, et al.
Publicado: (2014)

Association of Irisin/FNDC5 with ERRα and PGC-1α Expression in NSCLC
por: Nowińska, Katarzyna, et al.
Publicado: (2022)

Cancer as an infective disease: the role of EVs in tumorigenesis
por: Robado de Lope, Lucia, et al.
Publicado: (2022)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
por: Ortega-Franco, Ana, et al.
Publicado: (2020)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department
por: Sánchez, Juan C., et al.
Publicado: (2023)

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
por: Arriola, Edurne, et al.
Publicado: (2018)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma
por: Cox, Steven T., et al.
Publicado: (2018)

Corrigendum: Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma
por: Cox, Steven T., et al.
Publicado: (2020)

Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies
por: Pérez-Díez, Irene, et al.
Publicado: (2021)

Cost-effectiveness of diagnostic tests during follow-up in lung cancer patients: an evidence-based study
por: Rodríguez-Cano, Fernando, et al.
Publicado: (2023)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
por: Rocha, Pedro, et al.
Publicado: (2020)

Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data
por: Calvo, Virginia, et al.
Publicado: (2021)

R-Score: A New Parameter to Assess the Quality of Variants’ Calls Assessed by NGS Using Liquid Biopsies
por: Serna-Blasco, Roberto, et al.
Publicado: (2021)

Pit PGC
por: CERN PhotoLab
Publicado: (1973)

Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model
por: Martín-Ruiz, Asunción, et al.
Publicado: (2020)

HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02
por: Martín, Paloma, et al.
Publicado: (2015)

The PGC8 pit.
por: Jean-Luc Caron
Publicado: (1999)

The PGC8 pit.
por: Jean-Luc Caron
Publicado: (1999)

The PGC8 pit.
por: Jean-Luc Caron
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_vffgag2shtvkc68t1t4oja4vev